Compounding means a pharmacy makes a medicine for a patient’s particular need.
The FDA said pharmacies could not use cagrilintide to make such a medicine.
That means an offer to prescribe or compound cagrilintide today is not normal treatment. The publicly listed way to seek cagrilintide itself is through a registered research study on ClinicalTrials.gov.
Three names, three different meanings
- Cagrilintide is a long-lasting lab-made cousin of amylin, a hormone linked with fullness. It is still being tested.
- CagriSema is the experimental combination of cagrilintide and semaglutide.
- Semaglutide is already the ingredient in approved medicines called Ozempic, Wegovy, and Rybelsus.
Pick the question that brought you here
Is it real?Learn the difference between the drug being studied, the combination trial product, and an online offer.Can I get care?See how to look for a study or discuss approved choices.What did trials find?Read the useful result, the limits, and the missing answers.What might it cost?Understand why there is no official cagrilintide price yet.
Chapter recap
Cagrilintide is real research. It is not an approved treatment or a lawful compounded option as of September 2026.